Clomiphene citrateCAS# 50-41-9 |
- GW1929
Catalog No.:BCC1611
CAS No.:196808-24-9
- Balaglitazone
Catalog No.:BCC1395
CAS No.:199113-98-9
- Inolitazone
Catalog No.:BCC1652
CAS No.:223132-37-4
- GW9662
Catalog No.:BCC2260
CAS No.:22978-25-2
- Troglitazone
Catalog No.:BCC2016
CAS No.:97322-87-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 50-41-9 | SDF | Download SDF |
| PubChem ID | 3033832 | Appearance | Powder |
| Formula | C32H36ClNO8 | M.Wt | 598.08 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 50 mg/mL (83.60 mM) H2O : 1 mg/mL (1.67 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[4-[(Z)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid | ||
| SMILES | CCN(CC)CCOc1ccc(cc1)C(=C(Cl)c2ccccc2)c3ccccc3.OC(=O)CC(O)(CC(O)=O)C(O)=O | ||
| Standard InChIKey | PYTMYKVIJXPNBD-OQKDUQJOSA-N | ||
| Standard InChI | InChI=1S/C26H28ClNO.C6H8O7/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,3-4,19-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Clomiphene citrate Dilution Calculator
Clomiphene citrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.672 mL | 8.3601 mL | 16.7202 mL | 33.4403 mL | 41.8004 mL |
| 5 mM | 0.3344 mL | 1.672 mL | 3.344 mL | 6.6881 mL | 8.3601 mL |
| 10 mM | 0.1672 mL | 0.836 mL | 1.672 mL | 3.344 mL | 4.18 mL |
| 50 mM | 0.0334 mL | 0.1672 mL | 0.3344 mL | 0.6688 mL | 0.836 mL |
| 100 mM | 0.0167 mL | 0.0836 mL | 0.1672 mL | 0.3344 mL | 0.418 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Clomifene Citrate is a selective estrogen receptor modulator.
- Cocaine
Catalog No.:BCN1901
CAS No.:50-36-2
- Thalidomide
Catalog No.:BCC2248
CAS No.:50-35-1
- Phenylbutazone
Catalog No.:BCC4822
CAS No.:50-33-9
- beta-Estradiol
Catalog No.:BCN2194
CAS No.:50-28-2
- Estriol
Catalog No.:BCN2235
CAS No.:50-27-1
- Prednisolone
Catalog No.:BCC4830
CAS No.:50-24-8
- Hydrocortisone
Catalog No.:BCN2192
CAS No.:50-23-7
- Corticosterone
Catalog No.:BCN2203
CAS No.:50-22-6
- Cyclophosphamide
Catalog No.:BCC1185
CAS No.:50-18-0
- Ergocalciferol
Catalog No.:BCN2208
CAS No.:50-14-6
- Mitomycin C
Catalog No.:BCC2388
CAS No.:50-07-7
- Cortisone acetate
Catalog No.:BCC4771
CAS No.:50-04-4
- Mercaptopurine (6-MP)
Catalog No.:BCC1186
CAS No.:50-44-2
- Estradiol Benzoate
Catalog No.:BCC4779
CAS No.:50-50-0
- Reserpine
Catalog No.:BCN4960
CAS No.:50-55-5
- Oxytocin
Catalog No.:BCC5435
CAS No.:50-56-6
- Chloroquine diphosphate
Catalog No.:BCC3915
CAS No.:50-63-5
- Niclosamide
Catalog No.:BCC5081
CAS No.:50-65-7
- 5-Hydroxytryptamine
Catalog No.:BCC9204
CAS No.:50-67-9
- 1,3:2,4-Di-p-methylbenyliedene sorbitol
Catalog No.:BCC4847
CAS No.:54686-97-4
- Actinomycin D
Catalog No.:BCC2385
CAS No.:50-76-0
- Aspirin (Acetylsalicylic acid)
Catalog No.:BCC2097
CAS No.:50-78-2
- Ascorbic acid
Catalog No.:BCN2207
CAS No.:50-81-7
- Thymidine
Catalog No.:BCN5622
CAS No.:50-89-5
The fetal safety of clomiphene citrate: a population-based retrospective cohort study.[Pubmed:28334503]
BJOG. 2017 Oct;124(11):1664-1670.
OBJECTIVE: To evaluate whether exposure to Clomiphene citrate (CC) for ovulation induction is associated with major malformations overall or with specific fetal anomalies. DESIGN: We conducted a population-based retrospective cohort study. Exposure was defined as CC dispension from 2 months before conception through the first month of pregnancy. SETTINGS: Four databases were combined: medication, birth, hospitalization, and terminations of pregnancy. POPULATION: The study included all women in southern Israel who gave birth or underwent termination of pregnancy at Soroka Medical Center, from 1998 to 2009. METHODS: The rates of major malformations overall and six different subcategories of anomalies were evaluated. The crude odds ratio (OR) was calculated with a 95% confidence interval (95% CI). Subsequently the adjusted odds ratio (aOR) was calculated using multiple logistic regression models controlling for maternal age, pre-pregnancy diabetes, parity, ethnicity, the calendar year in which the birth/termination of pregnancy took place, smoking, and the use of gonadotropins and progesterone. MAIN OUTCOME MEASURES: Major malformations overall and specific fetal malformations by organ systems. RESULTS: Of 114 961 pregnant women, 1872 were exposed to CC. No association was detected between exposure to CC and rates of major malformations overall (aOR 1.08, 95% CI 0.88-1.32) or rates of subcategories of malformations. Exposure was not associated with anencephaly (aOR 2.27, 95% CI 0.44-11.71) or oesophageal atresia (aOR 3.681, 95% CI, 0.65-20.76). CONCLUSIONS: In this large population-based retrospective cohort study, exposure to CC was not associated with an increased risk of either rates of major malformations overall or rates of specific malformations. TWEETABLE ABSTRACT: An observational study: no increased risk for fetal malformations following exposure to Clomiphene citrate.
Clomiphene citrate versus letrozole with gonadotropins in intrauterine insemination cycles: A randomized trial.[Pubmed:28280800]
Int J Reprod Biomed (Yazd). 2017 Jan;15(1):49-54.
BACKGROUND: Clomiphene citrate is one of the effective drugs for infertility treatment due to oligo-ovulation or anovulation. Intrauterine insemination (IUI) is one of more adherent methods for treatment of infertile cases which is followed by controlled ovarian hyperstimulation (COH). OBJECTIVE: the aim of this study was to evaluate Clomiphene citrate versus letrozole with gonadotropins in IUI cycles. MATERIALS AND METHODS: In this prospective randomized trial, 180 infertile women who were referred to Milad Hospital were selected. The first group received 5 mg/day letrozole on day 3-7 of menstrual cycle. The second group received 100 mg/day Clomiphene in the same way as letrozole. In both groups, human menopausal gonadotropin was administered every day starting on day between 6-8 of cycle. Ovulation was triggered with urinary Human Chorionic Gonadotropin (5000 IU) when have two follicles of >/=16 mm. IUI was performed 36 hr later. RESULTS: The number of matured follicles, cycle cancellation, and abortion were the same in both groups. Endometrial thickness was higher at the time of human menopausal gonadotropin administration in letrozole group. Chemical and clinical pregnancy rates were much higher in letrozole group. Ovarian hyperstimulation was significantly higher in clomiphene group. CONCLUSION: Letrozole appears to be a good alternative to Clomiphene citrate with fewer side effects.
Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study.[Pubmed:28277124]
Gynecol Endocrinol. 2017 Jun;33(6):462-466.
BACKGROUND AND AIM: There are still open questions about ovulation induction in Clomiphene citrate-(CC)-resistant infertile women. Especially little is known about efficacy and safety of letrozole (LTZ) combined with low-dose highly purified human menopausal gonadotropin (Hp-HMG) in women with polycystic ovary syndrome (PCOS). METHODS: Prospective, single-arm single-center trial in 200 infertile PCOS patients refractory for at least three CC-treatment cycles. Women with hyperandrogenism took Diane-35 for at least 3 months. All patients got LTZ on day 3 for 5 d in combination with Hp-HMG, starting with 75 IU from cycle day 7 and maintained for up to 3 d. The maximum dose was 150 IU. Primary end-points were ongoing and clinical pregnancy rate, secondary end-points mono-follicular development, ovulation rate, OHSS, multiple pregnancy and early pregnancy loss. Major safety end-point was the incidence of adverse events. RESULTS: Within 395 cycles the ongoing pregnancy rate was 28.24%, for cycles 35.23%, for patients 68%. The rate of ovulation per cycle was 97.7%, percentage of mono-follicular development 70.9%. No severe OHSS, multiple pregnancy, local or systemic side effects were seen. CONCLUSIONS: LTZ combined with low-dose Hp-HMG is an effective and safe choice for reducing hyperstimulation and increasing pregnancy rate in CC-resistant women with PCOS.
